| Sezary Syndrome presenting with leonine facies and treated with low-dose subcutaneous alemtuzumab. | |
| | |
MedLine Citation:
|
PMID: 22136862 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Cutaneous T-cell lymphomas (CTCL) comprise a group of diseases characterized by the accumulation of malignant T cells within the skin. Sezary syndrome represents an aggressive form of CTCL, in which the skin is diffusely affected and the peripheral blood is involved. It is characterized by the triad of generalized erythroderma, lymphadenopathy, and neoplastic T cells (Sezary cells) in the skin, lymph nodes, and peripheral blood. Leonine facies is rare and corresponds to the morphologic manifestation of diffuse dermal infiltration of the face. It can occur in cutaneous T-cell lymphomas that progress during years without therapy. We present the case of a 54-year-old man with Sezary syndrome presenting with leonine facies, unresponsive to conventional therapies; he exhibited a promising response to subcutaneous low-dose alemtuzumab. |
| | |
Authors:
|
Ana Oliveira; Inês Lobo; Rosário Alves; Margarida Lima; Manuela Selores |
Publication Detail:
|
Type: Journal Article Date: 2011-11-15 |
Journal Detail:
|
Title: Dermatology online journal Volume: 17 ISSN: 1087-2108 ISO Abbreviation: Dermatol. Online J. Publication Date: 2011 |
Date Detail:
|
Created Date: 2011-12-05 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9610776 Medline TA: Dermatol Online J Country: United States |
Other Details:
|
Languages: eng Pagination: 6 Citation Subset: IM |
Affiliation:
|
Hospital de Santo António, Centro Hospitalar do Porto, Porto, Portugal. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Primary cutaneous actinomycosis caused by Actinomyces meyeri as first manifestation of HIV infection...
Next Document: Acquired perforating dermatosis associated with metastatic colon cancer.